Big Tobacco lights up e-cigarettesBMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f3418 (Published 24 May 2013) Cite this as: BMJ 2013;346:f3418
- Douglas Kamerow, chief scientist, RTI International, and associate editor, BMJ
E-cigarettes, more formally electronic nicotine delivery systems, were introduced in 2007. They are battery powered, cigarette shaped devices that vaporize nicotine so that it can be inhaled. E-cigarettes are currently a relatively tiny market. In the United States they accounted for about $500m (£330m; €390m) in sales last year, perhaps 0.5% of tobacco receipts.1
That is changing. The tobacco company Lorillard purchased the leading e-cigarette maker Blu last year. Reynolds American is expanding marketing of its Vuse e-cigarettes, and Altria, the largest US tobacco company, has announced that it will enter the e-cigarette market later this year with its own product.1 Marlboro e-cigarettes, anyone? The game is on.
This, of course, has public health advocates terrified. Just when we had Big Tobacco on the run, with US sales falling 3-4% a year, along comes a new product that may save them—as well as maintain the nicotine addiction that they depend on for sales. In fact, tobacco industry sales were down more than 6% last year, due in no small part to the increase in e-cigarette sales. Hence the recent acquisitions and announcements.1
Let us count the ways …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial